Literature DB >> 22009284

Multiple sclerosis: combination therapy in MS--still a valid strategy.

Bernd C Kieseier, Olaf Stüve.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22009284     DOI： 10.1038/nrneurol.2011.164

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  8 in total

Review 1.  Statins--a cure-all for the brain?

Authors:  Til Menge; Hans-Peter Hartung; Olaf Stüve
Journal:  Nat Rev Neurosci       Date:  2005-04       Impact factor: 34.870

Review 2.  A critical appraisal of treatment decisions in multiple sclerosis--old versus new.

Authors:  Bernd C Kieseier; Olaf Stüve
Journal:  Nat Rev Neurol       Date:  2011-04-05       Impact factor: 42.937

3.  Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

Authors:  Per Soelberg Sorensen; Jan Lycke; Juha-Pekka Erälinna; Astrid Edland; Xingchen Wu; Jette Lautrup Frederiksen; Annette Oturai; Clas Malmeström; Egon Stenager; Finn Sellebjerg; Helle Bach Sondergaard
Journal:  Lancet Neurol       Date:  2011-08       Impact factor: 44.182

4.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

5.  Statins as immunomodulators: comparison with interferon-beta 1b in MS.

Authors:  O Neuhaus; S Strasser-Fuchs; F Fazekas; B C Kieseier; G Niederwieser; H P Hartung; J J Archelos
Journal:  Neurology       Date:  2002-10-08       Impact factor: 9.910

6.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

7.  Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.

Authors:  G Birnbaum; B Cree; I Altafullah; M Zinser; A T Reder
Journal:  Neurology       Date:  2008-06-04       Impact factor: 9.910

8.  Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.

Authors:  R A Rudick; A Pace; M R S Rani; R Hyde; M Panzara; S Appachi; J Shrock; S L Maurer; P A Calabresi; C Confavreux; S L Galetta; F D Lublin; E-W Radue; R M Ransohoff
Journal:  Neurology       Date:  2009-06-09       Impact factor: 9.910
  8 in total
  1 in total

1.  Prediction of combination therapies based on topological modeling of the immune signaling network in multiple sclerosis.

Authors:  Melanie Rinas; Jakob Wirbel; Marti Bernardo-Faura; Inna Pertsovskaya; Vicky Pliaka; Dimitris E Messinis; Gemma Vila; Theodore Sakellaropoulos; Wolfgang Faigle; Pernilla Stridh; Janina R Behrens; Tomas Olsson; Roland Martin; Friedemann Paul; Leonidas G Alexopoulos; Pablo Villoslada; Julio Saez-Rodriguez
Journal:  Genome Med       Date:  2021-07-16       Impact factor: 11.117
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.